Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 84Terminated 18Withdrawn 6Active not recruiting 3Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × ixabepilone × Clear all
NCT00049244 2017-01-30

BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

R-Pharm

Phase 1 Unknown
Breast

Breast Neoplasms

NCT01454479 2011-10-19

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Chang Gung Memorial Hospital

Phase 1 Unknown
24 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡